Genomics studies have identified DLBCL subgroups with a constitutively activated PI3K/mTOR pathway: GCB- and ABC-DLBCL, belonging to the B-cell receptor signaling cluster [36], with GCB-DLBCL mostly falling into the newly described EZB subtype by Schmitz et al. [2] or Cluster 3 by Chapuy et al. [1]. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.